CompletedPhase 1

A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients

Germany41 participantsStarted 2024-06-14

Plain-language summary

This study will assess the safety and tolerability of OM-85-IN compared to placebo in healthy volunteers and mild asthmatic patients

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male and female subjects aged 18 to 55 years. Women will be considered for inclusion if they are:
✓. Body mass index (BMI) ≥18 and ≤32 kg/m2.
✓. Part II : History of mild asthma that is well controlled with Step 1 treatment according to GINA guidelines 2023 for at least 12 months prior to the Screening Visit, i.e., a history of respiratory symptoms such as wheeze, shortness of breath, chest tightness, cough, and limitation of airflow induced by aeroallergens.
✓. Part II: Forced Expiratory Volume in the first second (FEV1) ≥80% of predicted at Screening Visit.
✓. Part II : Positive skin prick test to common aeroallergens such as tree, weed, grass or house dust mites within 12 months prior to the Screening Visit
✓. Part II : Production of adequate sputum with ≥2 x 105 total non-squamous cells within 12 months to 2 weeks prior to V1A (Day -8)
✓. Part II : Positive reaction to Nasal Allergen Challenge (NAC) within 12 months to 2 weeks prior to baseline

Exclusion criteria

✕. Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs, lung function or electrocardiogram (ECG) at Screening Visit, which, in the opinion of the Investigator, may either put the subject at risk because ofvparticipation in the study or may influence the results of the study, or the subject's ability to participate in the study."
✕. Use of prohibited medication prior to study enrolment
✕. Part II - Long-term, daily treatment with inhaled corticosteroids.
✕. Part II - Exacerbation of asthma defined according to the GINA guideline 2023 as a progressive increase in symptoms of shortness of breath, cough, wheezing or chest tightness and progressive decrease in lung function, i.e., they represent a change from the patient's usual status that is sufficient to require treatment changes within 1 month prior to the Screening Visit.
✕. Part II - Concomitant allergies to seasonal aeroallergens which are anticipated to be or become active during study participation.
✕. Known allergy to IMP active substance and/or excipients or the challenge agent components.
✕. Specific immunotherapy in the past 3 years before Baseline, ongoing treatment with any specific immunotherapy or plan to receive such treatment during study participation.
✕. Previous or ongoing treatment with other bacterial lysates and/or probiotics (dietary supplements, medicinal products and/or other health products) within 30 days before Baseline.

What they're measuring

Percentage of subjects with treatment-emergent adverse events (TEAEs) (including clinically relevant findings from nasal inspection)

Timeframe: 28 days

Trial details

NCT IDNCT06486662

SponsorOM Pharma SA

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-02-19

View on ClinicalTrials.gov More Allergic Asthma trials